Issue of Debt

AstraZeneca PLC
13 September 2007


AstraZeneca launches and prices a EUR750 million debut eurobond

AstraZeneca PLC, rated A1 (stable) by Moody's and AA- (stable) by Standard &
Poor's, yesterday priced a successful debut eurobond transaction (the 'Bonds')
issuing a total of EUR750 million. The proceeds of the issue will be used for
general corporate purposes and to repay a portion of the outstanding US
commercial paper taken on in connection with the acquisition of MedImmune.

The transaction is issued off a new Euro Medium Term Note (EMTN) programme,
dated September 10th 2007, and is a EUR750 million, fixed rate issue with a
coupon of 5.125% maturing in January 2015.

'This transaction represents a further part of our refinancing of the
acquisition of MedImmune Inc, following our successful $6.9bn, 4-tranche SEC
Global issue last week. As with last week's issue, this transaction represents
an enhancement of our financial flexibility by diversifying further our sources
of funding. We undertook an extensive roadshow of investor meetings in London,
Paris and Frankfurt and are very pleased with the feedback on the AstraZeneca
credit, and the reception for us in the bond markets', said David Brennan, Chief
Executive Officer of AstraZeneca.

The Bonds will be issued to institutional investors outside the US in accordance
with Regulation S of the U.S. Securities Act 1933.  The Bonds will be admitted
to listing on the UKLA's Official List and to trading on the London Stock
Exchange's Fixed Income and Gilt Edged Market.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the
research, development, manufacture and marketing of prescription pharmaceuticals
and the supply of healthcare services. It is one of the world's  leading
bio-pharmaceutical companies with healthcare sales of $26.47 billion and leading
positions in sales of gastrointestinal, cardiovascular, neuroscience,
respiratory, oncology and infection products. AstraZeneca is listed in the Dow
Jones Sustainability Index (Global) as well as the FTSE4Good Index.

13 September 2007


Media Enquiries:

Edel McCaffrey,          Tel: [phone]

Steve Brown,             Tel: [phone]


Investor Relations:

Mina Blair,              Tel: [phone]

Jonathan Hunt,           Tel: [phone]

Karl Hard,               Tel: [phone]

Jorgen Winroth,          Tel: [phone]

Ed Seage,                Tel: [phone]

Pete Vozzo, (MedImmune)  Tel: + 1 301-398-4358


This announcement is for information only and does not constitute an offer or
invitation to subscribe for or purchase any securities.

The securities have not been registered under the U.S. Securities Act of 1933,
as amended (the 'Securities Act'), and no securities shall be offered or sold in
the United States or to U.S. persons (as those terms are defined in Regulation S
under the Securities Act) unless an exemption from the registration requirements
of the Securities Act is available.


                      This information is provided by RNS
            The company news service from the London Stock Exchange